WASHINGTON — Sen. Bill Cassidy (R-La.) released a report on Thursday criticizing the Food and Drug Administration for not tightening restrictions on the abortion pill mifepristone, and charging the agency with lackluster oversight of the companies that manufacture the drug.
“To this day, FDA continues to redact mifepristone-related records in an unprecedented manner,” the report claims. “This lack of transparency has led to unanswered questions.”
The report is the result of an investigation conducted by Cassidy and other Republicans on the Senate’s health committee into the compliance practices of Danco, which distributes the brand-name version of mifepristone, and two other companies that manufacture generic versions of the drug.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe